1548 — Genscript Biotech Share News
0.000.00%
Last trade - 00:00- HK$76.05bn
- HK$72.43bn
- $959.53m
Brief: Duke-Nus And Genscript Announce Notice Of Allowance For U.S. Patent Application For Sars-Cov-2 Surrogate Virus Neutralization Test
Brief: Genscript Biotech And Ligand Pharmaceuticals Enter Into Global Omniab Licensing Agreement
Brief: GNS Holdings' Long Position In Genscript Biotech Increased To 8.42% On May 14 - HKEX Filing
Brief: Genscript Biotech Says Trading In Shares Of Co Will Be Halted With Effect From 900 A.M. On Friday, 14 May 2021
Brief: Genscript Biotech To Issue 103 Mln New Shares At A Subscription Price Is HK$18.658/Share
Brief: Genscript Biotech Through Unit To Subscribe For Convertible Bonds In Amount Of US$70 Mln
HK-listed Genscript Biotech hits over 2-year high, GNS to buy 8% stake
Brief: Genscript Biotech Says Genscript Corp To Sell 61.8 Million Shares Of Co
Brief: Genscript Biotech Corp Says Unit Filed Form 6-K With U.S. SEC
Brief: Genscript Biotech Corp Says Unit Submitted Marketing Authorisation Application To European Medicines Agency For Approval Of Ciltacabtagene Autoleuce
Brief: Genscript Biotech Corp Posts Revenue For Year Of US$390.8 Million, Up 42.9%
Brief: Genscript Biotech Corp Sees An Adjusted Loss Of About US$154.5 Million To US$193.3 Million For Year
Brief: Genscript USA Says Received FDA Emergency Use Authorization For Use Of Cpass Sars-Cov-2 Neutralization Antibody Test In Convalescent Plasma Screening
Brief: Genscript Biotech Says Ex-Chairman Released On Bail On Feb. 9
Brief: Genscript Submits Application With FDA For Use Of Cpass Sars-Cov-2 Neutralization Antibody Test In Convalescent Plasma Screening
Brief: Genscript Biotech Says Unit To Initiate Rolling Submission Of Biologics License Application
Brief: Genscript Gets FDA Emergency Use Authorization For SARS-CoV-2 Neutralizing Antibody Detection Kit
Genscript Biotech says Chinese customs raided offices, shares at 20-month low
HK-listed Genscript Biotech hits 20-month low after Chinese customs raids offices